Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration, Oncology, and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GSK3B (GSK-3β) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | GSK3B Recombinant Protein (WT & Phospho-Mutants) Full-length, Tyr216 phosphorylated (active conformation), High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. |
View GSK3B Products |
| Isoform Selectivity Panel | GSK3A Recombinant Protein Human/Mouse orthologs available for cross-species selectivity screening. Mass Spec verified. |
View GSK3A Products |
| Substrate Protein | MAPT (Tau) Recombinant Protein Microtubule-associated protein substrate for phosphorylation assays. HEK293 expressed. |
View MAPT Products |
| Pathway Component | CTNNB1 (Beta-catenin) Recombinant Protein Wnt pathway substrate for functional GSK3B activity validation. |
View CTNNB1 Products |
| Gene Delivery | GSK3B Lentivirus Particles (Full-length ORF & Kinase-Dead) For stable cell line construction and pathway reporter assays. |
View GSK3B Products |
| Benchmark Ab | Anti-GSK3B Recombinant Rabbit mAb (Detection Grade) Sequence-defined. Suitable for Western Blot, IP, and IHC. |
View GSK3B Products |
| Validator | GSK3B siRNA Set For knockdown verification and specificity controls. |
View GSK3B Products |
| Related Target | AXIN1 Scaffold protein in β-catenin destruction complex; complementary screening target. |
View AXIN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (GSK3A vs GSK3B) | Homolog panel proteins strictly verified by mass spec; >95% purity enables accurate IC50 determination |
| Active Conformation Requirement | Pre-phosphorylated (Tyr216) recombinant protein; Kinase assay-ready format |
| Substrate Phosphorylation Validation | Native folded Tau (MAPT) and Beta-catenin substrates; HEK293 expressed for correct post-translational modifications |
| Off-target Kinase Screening | CDK5, ERK2 homolog proteins available for selectivity panels |
| False Positives in Screening | Validated siRNA and kinase-dead mutant lentivirus for orthogonal specificity checks |
Live GSK3B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Alzheimer's)
- ➤ Oncology Phase Studies
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for GSK3B therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive inhibitors to substrate-competitive, allosteric, and bifunctional degrader modalities. As first-generation lithium-mimetic approaches face selectivity challenges, the next wave of R&D targets isoform-specific inhibition (GSK3B vs GSK3A) and CNS-penetrant formulations for Alzheimer's disease. In oncology, paradoxical tumor suppression versus promotion effects are driving demand for biomarker-stratified trials. Early-phase therapies have encountered safety and selectivity bottlenecks, prompting a shift toward non-ATP-competitive pockets and targeted protein degradation to improve the therapeutic window.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Eli Lilly, AstraZeneca, Actuate Therapeutics | Alzheimer's Disease, Solid Tumors | Active Kinase Conformation (Need Tyr216-phosphorylated protein) |
| Small Molecule (Non-ATP-competitive / Allosteric) | Academic Consortia, Biotech | Bipolar Disorder, Diabetes, Neurodegeneration | Substrate Competition Assay (Need high-purity GSK3B + Tau/CTNNB1 substrate proteins) |
| Targeted Protein Degradation (PROTAC) | Arvinas, Emerging Biotech | Refractory Oncology, Neurodegeneration | Ternary Complex Formation (Need Native Fold Proteins) |
| Gene Modulation (siRNA / Lentivirus) | Preclinical Academic Labs | CNS Disorders | Knockdown Efficiency (Need validated siRNA & ORF lentivirus) |